BLU News and Press, BELLUS Health Inc. From 12/23/20

BELLUS Health (BLU) announces at-the-market distribution with Jefferies, pursuant to which the company may from time to time sell common shares of an aggregate offer price of up to $50M. Stock down 1.20% AH.Previously, Dec. 14: Dosing underway in BELLUS Health's mid-stage atopi...

BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), announces that it has entered today into an agreement (the “Sales Agreement”) with Jefferies LLC ("Jefferies") pursuant to which the Company may from time to time in th...

BELLUS Health (BLU) has dosed the first patient in the Phase 2 BLUEPRINT trial of BLU-5937, the company’s highly selective P2X3 antagonist, in patients with chronic pruritus associated with atopic dermatitis.The 128-subject trial will be randomized into one of two treatment a...

Topline results expected in Q4 2021 BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitizati...

BELLUS Health (BLU) has dosed the first patient in Phase 2b SOOTHE trial evaluating BLU-5937, a P2X3 antagonist, in patients with refractory chronic cough.The 300-subject trial will evaluate three doses of BLU-5937 (12.5 mg, 50 mg and 200 mg BID). The primary efficacy endpoint will be th...

Interim analysis expected in mid-2021, with topline results expected in Q4 2021 BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment...

BELLUS Health ([[BLU]] +4.0%) announces the appointment of Ramzi Benamar to the role of Chief Financial Officer.Mr. Benamar brings over two decades of biopharmaceutical expertise to the position. Prior to joining BELLUS Health, he served as CFO of DBV Technologies. Previously, he was Vic...

3 Penny Stocks To Watch Before The End Of 2020 The end of the year can become an exciting time for penny stocks. We tend to see sporadic breakouts and break downs, news-driven momentum, and technical patterns to follow. Where some worry about tax-loss selling toward the end of the year,...

BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced the appoin...

Billionaire investor Warren Buffett advises people not to time the market , because it’s a useless exercise. However, his recent buys seem to suggest he’s timing for something else — the COVID-19 vaccine. Berkshire Hathaway bought four pharma stocks in the t...